Cardiovascular effects of apelin infusion in healthy male subjects

Completed

• Conditions: cardiovasculaire ziekten; heart- and bloodvessel diseases

• Registration Number: NL-OMON39109
• Lead Sponsor: Eli Lilly

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

healthy male subjects
18-55 yrs, inclusive
BMI: 18.5-30.0 kg/m2, inclusive
non-smoking or less than 10 cigarettes/day

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacodynamics: hemodynamic assessments, cardiac index, ATII pressor test, NE<br /><br>pressor test and Glomerular Filtration Rate (GFR)<br /><br>Pharmacokinetics: plasma apelin and iohexol concentrations, pharmacokinetic<br /><br>parameters<br /><br>Safety: adverse events, vital signs, ECG-parameters, laboratory parameters,<br /><br>physical examination</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n/a</p><br>